Alternative Names: CJC-1295: Mod GRF 1-29, Ipamorelin: NNC 26-0161 CJC-1295 & Ipamorelin Studies and Research Data Research on Gastric Function and Ipamorelin Studies indicate that Ipamorelin may contribute to gastrointestinal activity by interacting with ghrelin receptors
Current evidence consistently supports associations with common symptoms such as nausea, vomiting, diarrhea, and constipation, whereas links to more serious complications including pancreatitis, gastroparesis, or intestinal obstruction remain weak or inconsistent
In addition, a head-to-head trial of semaglutide and liraglutide was conducted in the STEP 8 trial, with a mean weight loss of 17.1% in the semaglutide group, which was significantly more effective than liraglutide (mean weight loss of 6.6%)
Acute supplementation of taurine can increase lipolysis and reduce the contribution from glycolytic metabolism, thereby altering the fuel utilization and metabolic efficacy of exercise
Unlike other GHSs, ipamorelin does not significantly affect ACTH or cortisol levels, even at high doses, ensuring targeted GH release (1)